Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy

Inclusion Criteria: 1. aged ≥ 18 years and ≤ 75 years, female 2. early-stage breast cancer or locally advanced breast cancer 3. Patients who have completed adjuvant or neoadjuvant chemotherapy with nab-paclitaxel 4. The patient developed nab-paclitaxel induced peripheral neuropathy (Nab-PIPN), as defined by meeting any of the following criteria: Patient Neurotoxicity Questionnaire (PNQ) score ≥ Grade B, NCI-CTCAE (sensory and motor neuropathy) grade ≥ 1, or neuropathic pain score ≥ 4/10. 5. The patient voluntarily participated in this study, provided written informed consent, and agreed to cooperate with follow-up assessments. Exclusion Criteria: 1. Patients who have previously taken drugs that may affect the evaluation of Nab-PIPN symptoms, such as duloxetine, venlafaxine, gabapentin, pregabalin, and amitriptyline. 2. Patients with any other pathological conditions or diseases that could affect Nab-PIPN assessment, including alcoholic peripheral neuropathy, uremic peripheral neuropathy, diabetic peripheral neuropathy, thiamine deficiency-related peripheral neuropathy, and chronic axonal peripheral neuropathy of unknown etiology. 3. Patients who have contraindications for hyperbaric oxygen therapy, including pulmonary disorders (severe chronic obstructive pulmonary disease, bullous lung disease, acute or chronic pulmonary infection, uncontrolled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear diseases (eustachian tube dysfunction, recurrent vertigo), and ocular conditions (retinal detachment). 4. Patients with any disease history that may affect compliance, including severe mental disorders, cognitive impairment, substance abuse or addiction. 5. Karnofsky Performance Status score \< 80 6. Patients with any other conditions that the investigator deems unsuitable for participation in the study.